2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1681 Comparison of plasma cell-free DNA with bone marrow genomic DNA profiling for molecular assessment of myeloid neoplasms

Jiani N. Chai, MD, PhD, Nicholas Joseph Dcunha2, Fei Xu3, Erika Gedvilaite4, Anoop Balakrishnan Rema5, Aalap Darshak Parikh6, Anita S. Bowman7, Vandana Baloda, MD8, Monica Diosdado Rodriguez9, Jacklyn Casanova-Murphy10, Maria E. Arcila11, Mark Ewalt, MD12
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction:
Molecular assessment of myeloid neoplasms traditionally relies on serial bone marrow (BM) examinations, which are invasive and may limit testing frequency. Plasma cell-free DNA (cfDNA) sequencing offers a minimally invasive alternative, but its clinical performance remains incompletely validated. MSK-ACCESS Heme is a hybrid-capture next-generation sequencing assay designed to detect select somatic alterations across 115 genes in cfDNA from patients with hematologic malignancies. We compared plasma cfDNA profiling by MSK-ACCESS Heme results with BM genomic DNA (gDNA) sequencing by MSK-IMPACT Heme in patients with myeloid neoplasms.

Methods:

Paired cfDNA and BM aspirate gDNA samples were collected from patients with myeloid neoplasms. MSK-ACCESS Heme was performed on cfDNA while standard of care MSK-IMPACT Heme was performed on gDNA from the BM aspirate. The preliminary cohort comprised 11 sample pairs from 9 patients; eight pairs were within one day, and 3 pairs were collected 23-38 days apart with no documented intervening change in disease status. Following sequencing with MSK-ACCESS Heme (cfDNA) and MSK-IMPACT Heme (gDNA), somatic variant detection and variant allele frequency (VAF) were compared across overlapping assay targets. Pearson correlation and Wilcoxon signed-rank tests were used for statistical analysis.

Results:

The median patient age was 67 years (range, 22–85 years); 5 patients were male, and 4 were female. Diagnoses included acute myeloid leukemia (AML) (n=4 pairs), myelodysplastic syndrome (MDS) (n=3), chronic myelomonocytic leukemia (CMML) (n=3), and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (n=1). Disease status included newly diagnosed (n =3), persistent (n=4), relapsed (n=1), and remission (n=3). 

Considering only overlapping assay targets, all mutations identified in gDNA (n=57) were detected in plasma across all sample pairs. VAFs were strongly correlated between assays (Pearson r=0.93, P<0.001), with no significant difference between paired measurements (Wilcoxon P=0.43). Concordant alterations involved genes frequently mutated in myeloid neoplasms, including ASXL1, DNMT3A, FLT3, IDH2, KRAS, NPM1, NRAS, SF3B1, TET2, TP53, and U2AF1.

Among pairs collected within one day, 5 cases had no morphologically detectable peripheral blood blasts; VAFs remained  positively correlated with no significant difference (Pearson r=0.81, P<0.001; Wilcoxon P=0.18). Notably, in one patient with NPM1-mutated AML and 37% BM blasts, but no circulating blasts, ACCESS detected plasma NPM1 at a VAF closely mirroring IMPACT (5.25% versus 5.44%), along with additional concordant mutations. These findings underscore that plasma cfDNA profiling reflects global disease status rather than simply mirroring circulating disease, enabling variant detection even when blasts are confined to the bone marrow. 

ACCESS identified 9 low-level variants not detected, or only marginally supported, by IMPACT. Case-level review suggested that 7 of these variants represented low-level clonal hematopoiesis or subclonal myeloid alterations below IMPACT detection threshold. In a patient with MDS/MPN and concurrent Langerhans cell histiocytosis (LCH), BRAF p.V600E was attributed to LCH. In another patient with CMML and a small abnormal B-cell clone, MYD88 p.L265P was considered B-cell derived.

Conclusions:
Plasma cfDNA profiling by MSK-ACCESS Heme demonstrated high concordance with BM gDNA profiling by MSK-IMPACT Heme in patients with myeloid neoplasms. cfDNA testing reliably detected myeloid-associated variants even in the absence of circulating blasts and identified additional low-level alterations relevant to the primary myeloid neoplasm or reflecting other clonal process such as low-level clonal hematopoiesis, or concurrent hematologic disorders. Collectively, these findings support cfDNA sequencing as a minimally invasive approach for monitoring in myeloid neoplasms with the potential to capture the global disease status, beyond the cellular circulating component. An expanded analysis is ongoing to evaluate potential associations with diagnosis and disease burden.

 

Jiani N. Chai, MD, PhD: No relevant conflicts of interest to declare.